Endogenous estrogen exposure and chronic kidney disease; A 15-year prospective cohort study

Maryam Farahmand  
Research Institute for Endocrine Sciences

Fahimeh Ramezani Tehrani  (ramezani@endocrine.ac.ir)  
Shaheed Beheshti University of Medical Sciences

Davood Khalili  
Research Institute for Endocrine Sciences

Leila Cheraghi  
Research Institute for Endocrine Sciences

Fereidoun Azizi  
Research Institute for Endocrine Sciences

Research article

Keywords: Endogenous estrogen exposure, chronic kidney disease (CKD), menopause, menarche, estimated glomerular filtration rate (eGFR)

DOI: https://doi.org/10.21203/rs.3.rs-44508/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

**Background:** Despite strong evidence demonstrating the role of estrogen as a protective factor for kidney function in women, limited data are available regarding the influence of endogenous estrogen exposure (EEE) on chronic kidney disease (CKD). The present study aimed to assess the incidence of CKD in women with various levels of EEE.

**Methods:** In a prospective population-based study over a 15-year follow-up, a total of 3043 eligible women aged 30-70 years, participating in Tehran-Lipid and Glucose-Study were recruited and divided in two groups (EEE <11 and EEE ≥ 11 years). Cox’s proportional hazards model was applied to estimate the hazard ratio of CKD between the study groups, after adjusting for confounders.

**Results:** The total cumulative incidence rate of CKD at the median follow-up time of approximately 15.6 years was 50.1 per 1000 person years; 95% CI: 47.7–52.6); this was 53.9 per 1000 person years (CI, 50.2–57.8) and 47.1 per 1000 person years (CI, 44.0–50.4) in women with EEE <11 and EEE ≥ 11 years, respectively. The multivariate Cox model adjusted for age, BMI, smoking, hypertension and diabetes showed that the HR of developing CKD in women with EEE <11 years was significantly higher than in those with ≥ 11 years (HR: 4.0; 95% CI: 2.5, 6.3).

**Conclusion:** This study shows a higher hazard ratio of CKD progression in women with low EEE levels in their later life. Our results suggest that the early diagnosis and management of subsequent kidney diseases in these women may potentially prevent the complications of this disease.

Background

The kidney, a powerful endocrine organ, is an important modulator of endocrine function, and a main target for hormonal action\(^1\). Chronic kidney disease (CKD) can be determined as a persistent injury of the renal parenchyma which causes chronic deterioration of renal function that may progressively worse to end-stage kidney disease (ESKD)\(^1\).

Studies show that slower progression of CKD and lower incidence of ESKD in younger women compared to men, and omitting this gender protectively after menopause, suggests a role for female hormones\(^2-4\). While the mechanisms responsible for the protection of kidneys by these hormones, mainly estrogen, are not completely understood, it seems to be due to induced vasodilation in the renal vessels, enhancing the production of nitric oxide (NO), attenuation of inflammation and reduction in ischemia mediators\(^5-7\).

It has been shown that estrogen stimulates the release of NO resulting in vasodilation; NO deficiency can be associated with acceleration of kidney injury by reduction of vasodilation and endothelial dysfunction. Estrogen also decreases the synthesis of renin and angiotensin-converting enzyme (ACE), and increases angiotensinogen synthesis\(^8\). Experimental studies demonstrate that administration of continuous estradiol can prevent glomerulosclerosis and albuminuria\(^9\).
Despite existing strong evidence demonstrating the role of estrogen as a protective factor for kidney function in women, limited data are available regarding the influence of endogenous estrogen exposure (EEE) on chronic kidney disease (CKD); EEE can be calculated based on reproductive factors, including age at menarche, age at menopause, number and duration of pregnancies, lactation, and duration of oral contraceptive use. In this prospective study, we aimed to investigate the incidence and hazard ratio of CKD among women with lower durations of EEE compared to those with higher exposure, after adjustment for known confounders.

**Methods**

**Subjects**

Subjects of the present study were recruited from among participants of the Tehran Lipid and Glucose Study (TLGS), an ongoing prospective study, initiated in 1998, with the purpose of determining the prevalence of non-communicable disease (NCD) risk factors. There were 5226 women, aged 30-70 years selected for our study; after excluding those with CKD at baseline (n=1425), those with missing data of CKD (n=97) and those with missing data on age at menarche (n=1019), 3141 women remained; we further excluded those with missing data for calculating EEE (n=98) HRT users (n=87) and those without at least one follow-up (n=92); eventually 3043 women remained for the purpose of the present study.

The study flowchart is presented in Fig. 1.

**Study procedure:**

A standard questionnaire including information on demographics, smoking behavior, physical activity habits and medical history was completed via face-to-face interviews.

**Measurements:**

Using systolic and diastolic blood pressure (SBP and DBP) was measured twice after a 15 minutes rest in a sitting position on the right arm, and the mean was considered as the participants' blood pressure. Weight was measured with individuals minimally clothed, using digital scales (Seca 707: range 0.1–150 kg) and recorded to the nearest 0.1 kg. Height was measured in a standing position, using a tape meter, while shoulders were in normal alignment.

Blood samples were drawn between 7:00 and 9:00 am after 12 h of overnight fasting. All blood analyses were performed at the TLGS research laboratory on the day of blood collection. All sera were stored at −80°C until the time of testing. Plasma glucose was measured using an enzymatic colorimetric method with glucose oxidase. Serum concentrations of creatinine (Cr) were tested by kinetic colorimetric Jaffe. The sensitivity of the assay was 0.2 mg/dL (range, 18–1330 µmol/L (0.2–15 mg/dL). Reference intervals based on the manufacturer's recommendation was 53–97 µmol/L (0.6–1.1 mg/dL) in men. Intra-assay and inter-assay CVs were less than 3.1% at both baseline and follow-up phases. All biochemical assays
were performed using commercial kits (Pars Azmoon Inc., Tehran, Iran) by a Selectra 2 autoanalyzer (Vital Scientific, Spankeren, The Netherlands).

Definitions:

According to the Kidney Disease Outcome Quality Initiative guidelines (K/DOQI), CKD is defined as either kidney damage or Glomerular Filtration Rate (GFR) <60 mL/min/1.73 m2 for >3 months. In the present study, we estimated GFR using the abbreviated prediction equation, provided by the Modification of Diet in Renal Disease (MDRD) study as follows:

\[ \text{GFR} = 186 \times (\text{SCR})^{-1.154} \times (\text{Age})^{-0.203} \times 0.742 \times (0.742 \text{ if female}) \times (1.210 \text{ if African-American}) \]

In this equation, estimated GFR (eGFR) is expressed as mL/min per 1.73 m2 and serum creatinine (SCr) is expressed as mg/dL; based on the guidelines, we considered CKD as an eGFR > 60 mL/min/1.73 m2, occurring at any time during the follow-up period.

Endogenous estrogen exposure (EEE) was defined as the time interval between age at menarche and menopausal age or age at CKD event or end of follow-up, whichever occurred earlier. To consider only E2 dominant of menstrual cycles, we omitted the cumulative durations of progesterone dominant phases of menstrual as well as those of pregnancies and lactation (assumed 40 weeks for each birth or 20 weeks for each abortion).

Hypertension was defined as systolic blood pressure (SBP)/diastolic blood pressure (DBP) ≥ 140/90 mmHg or current treatment for diagnosed hypertension. Diabetes was defined as fasting plasma glucose (FPG) ≥ 7.0 mmol/l or 2-h post 75g glucose load ≥ 11.1 mmol/l or under current treatment for diagnosed diabetes. Smoking status was categorized as ever smoker (current/past) or never smoker.

Physical activity was measured as the MET value multiplied by the duration of activity in minutes multiplied by the frequency of activity per week. Each activity was weighted via its relative power, referred to as a MET; one MET shows the energy spent for an individual at rest (1 MET = 3.5 ml/kg.min of oxygen consumption). Energy expending was estimated based on the metabolic equivalent, duration of activity, and body weight. To get the total weekly leisure time energy expending the individual activities values was summed.

Statistical Analysis

Results are reported as mean and standard deviation (SD) for numerical variables and number (percentage) for categorical measures. For numerical variables with skewed distribution, median (interquartile range) was calculated. Using the Cubic Spline regression, participants were categorized into two groups according to cut-offs of EEE duration, of <11, and ≥11 years. Post hoc analysis was conducted using the cut off of 45 years for age at baseline.
Time to event was specified as a time of censoring or date of incidence of CKD or age at menopause, whichever happened first. Participants were censored as a result of death, loss to follow-up, or the end of the observation duration. For censored subjects, a negative event, the most recent follow-up visit was considered, as leaving the residence area; “time” was considered as the interval between the first and the last follow-up dates. The event date for CKD was defined as midtime between the dates of follow-up visit at which the CKD was recognized for the first time, and the last follow-up visit prior to diagnosis. Incidence rate of CVD was calculated per 1000 person years of follow up between those with EEE <11 and EEE ≥ 11 years. Cumulative incidence of CKD was measured via the Kaplan-Meier method and compared between these 2 groups, using the log-rank statistic.

Multivariable Cox proportional hazards regression model was used to estimate the hazard ratio (HR) and 95% confidence interval (CI) between groups (EEE< 11 and EEE ≥ 11 years ) which was adjusted for age, BMI, smoking, hypertension and diabetes. The proportional hazards assumption of the Cox models was assessed graphically. The Statistical Package for Social Sciences (SPSS version 20; SPSS Inc.) and STATA software (version 13; STATA Inc.) was used for data analysis.

Results

Characteristics of the study subjects according to the EEE cutoff value of 11 years are shown in Table 1. Mean ± SD age and menarcheal age of study subjects were 43.1±10.1, and 13.6 ± 1.5 years, respectively.

The median and 25-75%follow-up time for the current analysis was 15.6 and 12.4, 16.6 years. The overall incidence of CKD was 1598 (50.1 per 1000 person years; CI, 47.7–52.6); it was 769 (53.9 per 1000 person years; CI, 50.2–57.8), and 829 (47.1 per 1000 person years; CI, 44.0–50.4), in women with EEE<11 and EEE ≥ 11 years, respectively. As a result of subgrouping the participants into two age groups (<45, and ≥45years), the interaction between age and EEE duration was a statistically significant difference (P<0.001), in those aged < 45, the incidence of CKD were 537 (45.6 per 1000 person years; 95%CI: 41.9, 49.7), and 222 (22.4 per 1000 person years; 95%CI: 19.6, 25.5), in women with EEE<11 and EEE ≥ 11, respectively. In those aged ≥ 45, the incidence of CKD was 232 (92.5 per 1000 person years; 95%CI: 81.3, 105.2), and 607 (78.9 per 1000 person years; 95%CI: 72.9, 85.5) in women with EEE<11 and EEE ≥ 11, respectively. HRs for CKD events are presented in table2 and figure 2.

In the crude model, HRs of CKD in women with EEE< 11 years in subgroup of women aged<45 was 2.18 (95% CI, 1.9, 2.5); it was 1.18(95% CI, 1.0, 1.4) in those aged ≥45; after adjustment for age, BMI, smoking, hypertension and diabetes; HR of CKD incidence in women with EEE< 11 years in the subgroup of women aged<45 years was 2.66(95% CI, 2.2, 3.2), whereas in the subgroup aged ≥45 years, it was 1.22 (95% CI, 1.04, 1.4).

Discussion
To the best of our knowledge, this is the first study reporting the effects of endogenous estrogen exposure on chronic kidney disease. We found that after adjustment for all influencing variables, the hazard ratio of CKD among those women with > 11 years of EEE is four fold (95% CI: 2.5, 6.3, P<0.001) that of those with ≥ 11 years of exposure. An adverse effect even stronger among those women aged <45 2.7(95% CI: 2.2, 3.2) vs. 1.22(1.04, 1.4) in women aged ≥ 45 y.

There is controversy about the impact of sex hormones on renal function and disease as well as the gender dependency of CKD; the lower susceptibility of women could be due to absence of testosterone or the presence of estrogen via elevated synthase production nitric oxide in kidneys.

It has been shown that estrogen may affect kidney function through several pathways including improved metabolism, selectivity of Angiotensin Type 2 (AT2) receptor signaling, diminished oxidative stress, and differential renin-angiotensin system (RAS). There is some evidence that NO deficiency can be associated with acceleration of renal injury, based on receptors that impaired vasodilation and endothelial dysfunction have been reported in CKD.

Estradiol may improve kidney function by suppressing the transforming growth factor β-1 (TGF-β-1) that induces mesangial cell apoptosis, and enhancing mesangial cell growth by up-regulating NO synthase activity via vascular agents; furthermore, estrogen receptor α that largely expressed in the kidneys, has the opposite effect of apoptosis in podocytes and also acts as a regulator of renal sodium and potassium homeostasis and the renin angiotensin pathway. Several studies have report the anti-apoptotic and anti-fibrotic effects of endogenous estrogens in the kidney, which may partly explain the protective effect of estrogen on kidney. Estrogen may also have kidney protective effects by reducing renin and angiotensin-converting enzyme (ACE) synthesis and increasing angiotensinogen synthesis. In addition, estrogen acts as a mediator by reducing arterial pressure via signaling the AT2 receptor and ACE2. Animal studies reveal the acceleration of progression of glomerulosclerosis due to estrogen shortage, resulting in diminished glomerular permeability and ischemia-reperfusion damage.

Endogenous estrogen has been introduced as an important influential factor in NCDs (such as CKD) for its promotion of angiogenesis and vasodilation and decreasing of reactive oxygen species, oxidative stress, and fibrosis. Shorter durations of EEE have been reported to be associated with increased risk of osteoporosis, total mortality, venous thromboembolism and CVD. However, to the best of our knowledge the association between EEE and CKD has not been reported before.

We found that the impact of the duration of EEE on CKD among younger women is even stronger than in older counterparts, an important finding with high clinical utility given the higher morbidity and mortality of younger women with CKD. However with ageing, this association weakens, possibly due to over expression of other known risk factors of CKD for instance diabetes and hypertension.
This study is strengthened by the use of a comprehensive population based data set with a long enough follow-up, large sample size and precise estimation of CKD and influential factors, which enabled us to perform survival analysis, adjusted for the most important potential confounders; however, it does have some limitations. The main one is, as in most epidemiologic studies, we have not repeated Cr measurements within 3 months to confirm a chronic reduction in GFR. Second, recall bias for some components that been used for calculation of EEE; however, repeating these measurements every three years may reduce the risk of this bias. Although we tried to adjust our results for major known confounders for which data were available, other potential influencing factors such as diet have not been considered.

**Conclusion**

Our findings showed that lower duration of endogenous estrogen exposure especially among reproductive age women can be considered as a risk factor for CKD; and the early diagnosis of this susceptible group may improve their short term and long term morbidities.

**Declarations**

**Ethics approval and consent to participate** The medical ethics committee of this institute approved the study proposal (IR.SBMU.ENDOCRINE.REC.1397.284) and was in adherence with the Declaration of Helsinki and written informed consent was obtained from all participants.

**Consent for publication** Informed consent for publication was obtained from all participants.

**Availability of data and materials** The datasets generated and/or analyzed during the current study are not publicly available due to confidentiality considerations.

**Competing interests** The authors declare that they have no conflict of interest.

**Funding** This study was supported by the Research Institute for Endocrine Sciences (No.1397.284).

**Authors’ contributions** MF contributed to the study design and execution, data analysis, manuscript drafting and critical discussion. FRT contributed to the study design and execution, data analysis, manuscript drafting and critical discussion. DK contributed to the study design, and data analysis and manuscript drafting. LC contributed to the data analysis. FA contributed to the study design and execution and manuscript drafting. All authors have read and approved the manuscript.

**Acknowledgements** We are beholden to all the study participants for the in substantial time and effort given to our study. Thanks are also due to the research staff at the TLGS Unit and personnel of the Endocrine Research Laboratory. The authors wish to acknowledge Ms. Niloofar Shiva for critical editing of English grammar and syntax of the manuscript.

**Author details**
1 Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2 Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

3 Department of Epidemiology and Biostatistics, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

4 Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Abbreviations

EEE: Endogenous estrogen exposure; CKD: Chronic kidney disease; eGFR: estimated glomerular filtration rate; ESKD: End-stage kidney disease; NO: Nitric oxide; ACE: Angiotensin-converting enzyme; TLGS: Tehran Lipid and Glucose Study; NCD: Non-communicable Disease; CVD: Cardiovascular disease; SCr: Serum creatinine; K/DOQI: Kidney Disease Outcome Quality Initiative guidelines; MDRD: Modification of Diet in Renal Disease; FPG: Fasting plasma glucose; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; SD: Standard deviation; CI: Confidence interval; AT2: Angiotensin Type 2; RAS: renin-angiotensin system; ACE: Angiotensin-converting enzyme.

References

1. Akchurin M. Chronic Kidney Disease and Dietary Measures to Improve Outcomes. Pediatric Clinics. 2019;66(1):247–67.

2. Silbiger S, Neugarten J. Gender and human chronic renal disease. Gend Med. 2008;5 Suppl A:S3-s10.

3. Kummer S, von Gersdorff G, Kemper MJ, Oh J. The influence of gender and sexual hormones on incidence and outcome of chronic kidney disease. Pediatr Nephrol. 2012;27(8):1213–9.

4. Coggins CH, Breyer Lewis J, Caggiula AW, Castaldo LS, Klahr S, Wang SR. Differences between women and men with chronic renal disease. Nephrol Dial Transplant. 1998;13(6):1430–7.

5. Baylis C. Nitric oxide deficiency in chronic kidney disease. Am J Physiol Renal Physiol. 2008;294(1):F1–9.

6. Guetta V, Quyyumi AA, Prasad A, Panza JA, Waclawiw M, Cannon RO 3. The role of nitric oxide in coronary vascular effects of estrogen in postmenopausal women. Circulation. 1997;96(9):2795–801.

7. Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Shaul PW. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest. 1999;103(3):401–6.
8. Cobo G, Hecking M, Port FK, et al. Sex and gender differences in chronic kidney disease: progression to end-stage renal disease and haemodialysis. Clin Sci (Lond). 2016;130(14):1147–63.

9. Catanuto P, Doublier S, Lupia E, et al. 17 beta-estradiol and tamoxifen upregulate estrogen receptor beta expression and control podocyte signaling pathways in a model of type 2 diabetes. Kidney Int. 2009;75(11):1194–201.

10. de Kleijn MJ, van der Schouw YT, Verbeek AL, Peeters PH, Banga JD, van der Graaf Y. Endogenous estrogen exposure and cardiovascular mortality risk in postmenopausal women. Am J Epidemiol. 2002;155(4):339–45.

11. Azizi F, Ghanbarian A, Momenan AA, et al. Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II. Trials. 2009;10(1):5.

12. K/DOQI clinical. practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–266.

13. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–70.

14. Lenfant C, Chobanian AV, Jones DW, Roccella EJ. Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): resetting the hypertension sails. Hypertension. 2003;41(6):1178–9.

15. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26(Suppl 1):S5–20.

16. Farahmand M, Ramezani Tehrani F, Khalili D, Cheraghi L, Khomami MB, Azizi F. Association between duration of endogenous estrogen exposure and cardiovascular outcomes: A population-based cohort study. Life Sci. 2019;221:335–40.

17. Momenan AA, Delshad M, Mirmiran P, Ghanbarian A, Azizi F. Leisure Time Physical Activity and Its Determinants among Adults in Tehran: Tehran Lipid and Glucose Study. Int J Prev Med. 2011;2(4):243–51.

18. Reckelhoff JF, Samson WK. Sex and gender differences in cardiovascular, renal and metabolic diseases. Am J Physiol Regul Integr Comp Physiol. 2015;309(9):R1057-9.

19. Forte P, Kneale BJ, Milne E, et al. Evidence for a difference in nitric oxide biosynthesis between healthy women and men. Hypertension. 1998;32(4):730–4.

20. Neugarten J, Ding Q, Friedman A, Lei J, Silbiger S. Sex hormones and renal nitric oxide synthases. J Am Soc Nephrol. 1997;8(8):1240–6.

21. Xiao S, Gillespie DG, Baylis C, Jackson EK, Dubey RK. Effects of estradiol and its metabolites on glomerular endothelial nitric oxide synthesis and mesangial cell growth. Hypertension. 2001;37(2):645–50.

22. Park YJ, Kim JM. Klotho and Postmenopausal Hormone Replacement Therapy in Women with Chronic Kidney Disease. J Menopausal Med. 2018;24(2):75–80.
23. Baylis C. Nitric oxide deficiency in chronic kidney disease. American Journal of Physiology-Renal Physiology. 2008;294(1):F1–9.

24. Dixon A, Maric C. 17β-Estradiol attenuates diabetic kidney disease by regulating extracellular matrix and transforming growth factor-β protein expression and signaling. American Journal of Physiology-Renal Physiology. 2007;293(5):F1678–90.

25. PETRICA L, C. GLUHOVSCHI, and VELCIOV S. Chronic kidney disease and the involvement of estrogen hormones in its pathogenesis and progression. Rom J Intern Med. 2012;50(2):135–44.

26. Potier M, Elliot SJ, Tack I, et al. Expression and regulation of estrogen receptors in mesangial cells: influence on matrix metalloproteinase-9. J Am Soc Nephrol. 2001;12(2):241–51.

27. Kummer S, Jeruschke S, Wegerich LV, et al. Estrogen receptor alpha expression in podocytes mediates protection against apoptosis in-vitro and in-vivo. PloS one. 2011;6(11):e27457.

28. Tremblay AM, Dufour CR, Ghahremani M, Reudelhuber TL, Giguere V. Physiological genomics identifies estrogen-related receptor α as a regulator of renal sodium and potassium homeostasis and the renin-angiotensin pathway. Mol Endocrinol. 2010;24(1):22–32.

29. Lim VS, Henriquez C, Sievertsen G, Frohman LA. Ovarian function in chronic renal failure: evidence suggesting hypothalamic anovulation. Ann Intern Med. 1980;93(1):21–7.

30. Elliot SJ, Berho M, Korach K, et al. Gender-specific effects of endogenous testosterone: female alpha-estrogen receptor-deficient C57Bl/6J mice develop glomerulosclerosis. Kidney Int. 2007;72(4):464–72.

31. Hutchens MP, Fujiyoshi T, Komers R, Herson PS, Anderson S. Estrogen protects renal endothelial barrier function from ischemia-reperfusion in vitro and in vivo. American Journal of Physiology-Renal Physiology. 2012;303(3):F377–85.

32. Kumar S, Bogle R, Banerjee D. Why do young people with chronic kidney disease die early? World J Nephrol. 2014;3(4):143–55.

33. Islam TM, Fox CS, Mann D, Muntner P. Age-related associations of hypertension and diabetes mellitus with chronic kidney disease. BMC Nephrol. 2009;10(1):17.

34. Cobo G, Cordeiro AC, Amparo FC, Amodeo C, Lindholm B, Carrero JJ. Visceral adipose tissue and leptin hyperproduction are associated with hypogonadism in men with chronic kidney disease. Journal of Renal Nutrition. 2017;27(4):243–8.

35. Cheung KL, Stefanick ML, Allison MA, et al. Menopausal symptoms in women with chronic kidney disease. Menopause (New York NY). 2015;22(9):1006.

Tables

Table 1

Characteristics of subjects in groups by cut-off of exposure durations of endogenous estrogen.
| Variables                                      | Duration of endogenous estrogen exposure |  |  |  |
|------------------------------------------------|------------------------------------------|--|--|--|
|                                                | Group 1 <11 years                        | Group 2 ≥11 years | Total |
| Subjects (no)*                                 | 1429 (47.0)                              | 1614(53.0)        | 3043(100) |
| Age(years)**                                   | 39.2±8.8                                 | 46.6±9.8          | 43.1±10.1 |
| Menarcheal age(years)**                        | 13.7±1.4                                 | 13.5±1.5          | 13.6±1.5 |
| Body mass index (kg/m²)**                      | 28.1±4.6                                 | 28.5±4.8          | 28.3±4.7 |
| Hypertension (yes)*                            | 195 (13.8)                               | 425(26.8)         | 620(20.6) |
| Antihypertensive drug use*                     | 60(4.2)                                  | 150(9.3)          | 210(6.9) |
| Angiotensin-converting-enzyme inhibitor use*   | 9 (0.6)                                  | 19(1.2)           | 28(0.9) |
| Diabetes type 2*                               | 110 (7.9)                                | 238(15.1)         | 348(11.7) |
| Anti-diabetes type 2 drug use*                 | 39(2.7)                                  | 92(5.7)           | 131(4.3) |
| Ever Smoker (yes) *                            | 82(5.8)                                  | 72(4.5)           | 154(5.1) |
| eGFR (ml/min per 1.73 m²)                      | 71.9±8.5                                 | 70.7±8.0          | 71.3±8.3 |
| Creatinine (mg/dl)**                           | 0.94±0.08                                | 0.92±0.08         | 0.93±0.06 |
| Physical activity (MET- min/week)**            | 1639±2350.5                              | 1577.7±2049.4     | 1606.7±2195.2 |
| Menopause status (yes)*                        | 345(24.1)                                | 1420(88.0)        | 1765(58) |
| Menopausal age(years)**                        | 44.1±6.6                                 | 50.0±4.0          | 48.8±5.2 |
| Total duration of pregnancies (years)**        | 2.72±1.4                                 | 3.09±1.5          | 2.90±1.5 |
| Total duration of hormonal contraceptive use (years)** | 0.55±1.0                                | 0.47±0.5          | 0.53±0.9 |
| Total duration of breastfeeding (weeks)**       | 4.35±2.6                                 | 2.25±1.6          | 3.7±2.5 |
| Follow-up time (years)**                       | 15.5(12.2,16.5)                          | 15.6(12.5,16.6)   | 15.6(12.4,16.6) |

Note: ANOVA test, Mann-Whitney test, and Chi-square test were used as appropriate.
* Number and percentage
** Mean± SD
***Median (Interquartile range)

Note: eGFR estimated glomerular filtration rate; Body mass index & age are presented at baseline; Total duration of hormonal contraceptive use was calculated only in contraceptive users. Menopause status was assessed during follow-up or before event or censoring. Menopausal age was calculated among participants who had reached menopause. MET, metabolic equivalent task.

Note: Group1: Endogenous estrogen exposure duration <11 years, group, 2: Endogenous estrogen exposure duration ≥11 years.

### Table 2

Unadjusted and multiple adjusted hazard ratios of incident CKD by cut off value of 11 years for duration of EEE and subgroups of age at baseline
| Endogenous estrogen exposure duration | Incidence of CKD | Unadjusted | Adjusted* |
|-------------------------------------|------------------|------------|-----------|
|                                     | crude number (number per 1000 person years) | HR (95% CI) | Pvalue    |
|                                     | (95% CI)         | HR (95% CI) | Pvalue    |
| **Group 1** (<11 years) N=1429      | 769 (53.9) (50.2, 57.8) | 1.17 (1.1, 1.3) | 0.002     | 4.0 (2.5, 6.3) | <0.001 |
| **Group 2** (≥11 years) N=1614      | 829 (47.1) (44.0, 50.4) | Ref         | Ref       | Ref         | Ref     |
| **<45 years N=1860**                | 537 (45.6) (41.9, 49.7) | 2.2 (1.9, 2.5) | <0.001     | 2.7 (2.2, 3.2) | <0.001 |
| **≥45 years N=1183**                | 222 (22.4) (19.6, 25.5) | Ref         | Ref       | Ref         | Ref     |
| **Group 1** (<11 years) N=309        | 232 (92.5) (81.3, 105.2) | 1.17 (1.0, 1.4) | 0.03       | 1.22 (1.04, 1.4) | 0.01   |
| **Group 2** (≥11 years) N=874        | 607 (78.9) (72.9, 85.5) | Ref         | Ref       | Ref         | Ref     |

*Adjusted for baseline age and body mass index, smoking, hypertension, diabetes type 2.

Note: CI, Confidence interval; HR, Hazard ratio

Abbreviations: CKD, Chronic Kidney disease; EEE, Endogenous Estrogen Exposure.

**Figures**
Female participants of TLGS, age $\geq 30$ y
n=5226

Participants followed for CKD event, n=3141

Excluded:
Those with:
- CKD at baseline, n=1425
- Women with missing data of CKD, n=97
- Women with missing data of age at menarche, n=1019

Excluded:
Those with:
- Missing data for calculating EEE, n=98
- HRT users, n=87
- Lost to follow-up, n=92

Followed:
Those with:
CKD event, n=1598
(52.5%)
Till end of March 2017

Followed:
Those with:
No CKD event, n=1445
(47.5%)
Till end of March 2017

**Figure 1**

Study flowchart. Abbreviations: TLGS, Tehran Lipid and Glucose Study; CKD, Chronic Kidney Disease; EEE, Endogenous Estrogen Exposure; HRT, Hormone Replacement Therapy.
Figure 2

Kaplan-Meier cumulative estimates of incidence rates of CVD in subjects, according to the cutoff of endogenous estrogen exposure duration. A: Total of participants; B: Participants with <45 years; C: Participants with ≥ 45 years. Note: Endogenous estrogen exposure duration <11 years (solid line), and Endogenous estrogen exposure duration ≥ 11 years (dotted line).